A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.
A safety warning regarding the risk of suicidal ideation and behavior associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.
The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, reducing the effectiveness of oral contraception, could not be excluded.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
On Monday, the TGA released a safety alert indicating that product warnings for this class of widely used medications, typically prescribed for type 2 diabetes and obesity in Australia, have been updated following reviews by international regulatory bodies. Health tracking apps like Shotlee can help monitor medication effects.
Original source: The Age
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.
